Piramal Enterprises Ltd (PEL) on Friday said the National Company Law Tribunal has approved the demerger of its pharmaceutical business and simplification of corporate structure.
With this, the company can now go ahead with its plans to have two separate listed entities -- PEL, a non-banking financial company and Piramal Pharma Ltd (PPL), the company said in a regulatory filing.
"We are on track to achieve the completion of demerger and separate listing of Piramal Pharma by the third quarter of the current financial year," PEL Chairperson Ajay Piramal said.
Last October, the PEL board approved the demerger of the pharma business and simplification of the corporate structure.
It has already obtained approvals from RBI, SEBI, stock exchanges, creditors and equity shareholders.
PEL said in July this year it had also received RBI approval for the NBFC licence. Subsequent to the demerger, PEL said it as an NBFC will have a loan book of nearly USD 9 billion, while the pharma firm will be a significant player with revenues of nearly USD 1 billion.
Under the demerger scheme, four fully paid-up equity shares of PPL of Rs 10 each would be issued to PEL shareholders for every one fully paid-up equity share in PEL with face value of Rs 2 each held by them.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app